Development status and future prospects for a vaccine against Chlamydia trachomatis infection

Notice: Please note that this document may not be the Version of Record of the work

Louise M. Hafner; David P. Wilson; Peter Timms


Scholarcy highlights

  • Notice: Please note that this document may not be the Version of Record of the work
  • Primary genital tract infections of female mice with elementary bodies of the mouse-adapted C.muridarum strain are enough to cause tubal dilatation since a consistent observation is the development of hydrosalpinx shortly after initial chlamydial infection in this model
  • C.trachomatis and showed that it could protect against trachoma in a nonhuman primate model. These plasmid-free strains could be our best chance of a vaccine that can generate sufficiently strong immunity, involving both B and T cell responses, to an array of important antigens, in the absence of adverse pathology
  • The other recent breakthrough that could significantly accelerate vaccine research is that we have the ability to genetically manipulate Chlamydia. This major achievement that still has some technical challenges, means that potentially we can delete, or inactivate, key genes to understand their role in pathogenesis, and this should eventually result in a controlled means to produce a live attenuated vaccine strain that is unable to cause adverse pathology
  • Chlamydia have established intracellular infection, cells of the adaptive immune system, and T helper 1 type CD4+ T cells secreting IFN-g are required for effective clearance of primary infection and to protect from re-infection

Need more features? Save interactive summary cards to your Scholarcy Library.